Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Biomerica Inc

Healthcare US BMRA

1.9099USD
0.06(3.24%)

Last update at 2026-06-23T14:46:00Z

Day Range

1.861.91
LowHigh

52 Week Range

1.874.60
LowHigh

Fundamentals

  • Previous Close 1.85
  • Market Cap6.67M
  • Volume1714
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.26800M
  • Revenue TTM4.33M
  • Revenue Per Share TTM1.61
  • Gross Profit TTM 0.19M
  • Diluted EPS TTM-1.61

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-05-31 2024-05-31 2023-05-31 2022-05-31 2021-05-31
Type yearly yearly yearly yearly yearly
Date 2025-05-31 2024-05-31 2023-05-31 2022-05-31 2021-05-31
Income before tax -4.97200M -5.93600M -7.08900M -4.50732M -6.45598M
Minority interest - - - - -
Net income -4.97300M -5.97800M -7.14000M -4.53104M -6.46904M
Selling general administrative 4.61M 5.49M 6.08M 5.70M 4.61M
Selling and marketing expenses - - - - -
Gross profit 0.50M 0.61M 0.45M 2.98M 0.50M
Reconciled depreciation 0.40M 0.37M 0.35M 0.59M 0.38M
Ebit -5.13700M -6.36700M -7.22300M -4.53396M -6.52248M
Ebitda -4.73700M -5.99300M -6.87200M -3.91250M -6.07976M
Depreciation and amortization 0.40M 0.37M 0.35M 0.62M 0.44M
Non operating income net other - - - - 0.07M
Operating income -5.13700M -6.36700M -7.22300M -4.53396M -6.52248M
Other operating expenses 10.45M 11.78M 12.56M 23.41M 13.72M
Interest expense - - - 0.03M 0.00037M
Tax provision 0.00100M 0.04M 0.05M 0.02M 0.01M
Interest income 0.17M 0.43M 0.13M 0.03M 0.07M
Net interest income 0.17M 0.43M 0.13M 0.03M 0.07M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00100M 0.04M 0.05M 0.02M 0.01M
Total revenue 5.31M 5.42M 5.34M 18.87M 7.20M
Total operating expenses 5.63M 6.98M 7.67M 7.51M 7.02M
Cost of revenue 4.81M 4.80M 4.89M 15.89M 6.70M
Total other income expense net 0.17M 0.43M 0.00100M 0.03M 0.07M
Discontinued operations - - - - -
Net income from continuing ops -4.97300M -5.97800M -7.14000M -4.53104M -6.46904M
Net income applicable to common shares - - -7.14000M -4.53104M -6.46904M
Preferred stock and other adjustments - - - - -
Breakdown 2025-05-31 2024-05-31 2023-05-31 2022-05-31 2021-05-31
Type yearly yearly yearly yearly yearly
Date 2025-05-31 2024-05-31 2023-05-31 2022-05-31 2021-05-31
Total assets 5.95M 9.25M 14.45M 11.37M 11.82M
Intangible assets 0.23M 0.21M 0.17M 0.17M 0.29M
Earning assets - - - - -
Other current assets 0.26M 0.24M 0.30M 0.00045M 0.00026M
Total liab 1.84M 2.66M 2.73M 3.05M 2.59M
Total stockholder equity 4.11M 6.59M 11.72M 8.32M 9.23M
Deferred long term liab - - - - -
Other current liab 1.03M 1.50M 1.24M 0.88M 0.54M
Common stock 0.20M 1.35M 1.35M 1.03M 0.98M
Capital stock 0.20M 1.35M 1.35M 1.03M 0.98M
Retained earnings -53.16800M -48.19500M -42.21700M -35.07738M -28.39477M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.08M 0.00036M 0.26M
Cash 2.40M 4.17M 9.72M 5.92M 4.20M
Cash and equivalents - - - - -
Total current liabilities 1.74M 2.20M 1.95M 2.01M 1.30M
Current deferred revenue 0.06M 0.09M 0.06M 0.05M -
Net debt -1.94100M -3.38500M -8.63700M -4.53740M -2.57980M
Short term debt 0.36M 0.33M 0.30M 0.34M 0.33M
Short long term debt - - - - -
Short long term debt total 0.46M 0.79M 1.08M 1.38M 1.62M
Other stockholder equity 57.17M 53.54M 52.70M 42.45M 36.69M
Property plant equipment - - 1.25M 1.52M 1.86M
Total current assets 4.88M 7.73M 12.80M 9.43M 9.23M
Long term investments 0.17M 0.17M 0.17M 0.17M 0.17M
Net tangible assets - - 11.56M 8.16M 8.93M
Short term investments - - - - -
Net receivables 0.73M 0.95M 0.72M 0.77M 1.46M
Long term debt - - - - -
Inventory 1.49M 2.38M 2.06M 2.42M 3.21M
Accounts payable 0.29M 0.29M 0.34M 0.74M 0.43M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.10500M -0.10200M -0.11000M -0.07394M -0.04796M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.98M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -28.39477M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.11M 0.20M 0.08M 0.10M 0.26M
Deferred long term asset charges - - - - -
Non current assets total 1.07M 1.52M 1.66M 1.95M 2.59M
Capital lease obligations 0.46M 0.79M 1.08M 1.38M 1.62M
Long term debt total - - - - -
Breakdown 2025-05-31 2024-05-31 2023-05-31 2022-05-31 2021-05-31
Type yearly yearly yearly yearly yearly
Date 2025-05-31 2024-05-31 2023-05-31 2022-05-31 2021-05-31
Investments -0.03700M -0.11500M -0.07800M -0.17034M -0.29558M
Change to liabilities - - -0.08000M 0.39M -0.40333M
Total cashflows from investing activities -0.03700M -0.11500M -0.07800M -0.17034M -0.29558M
Net borrowings - - - - -
Total cash from financing activities 2.11M -0.08100M 9.39M 2.39M 1.11M
Change to operating activities - - -0.20100M 0.28M 0.91M
Net income -4.97300M -5.97800M -7.14000M -4.53104M -6.46904M
Change in cash -1.77000M -5.54900M 3.80M 1.72M -4.44172M
Begin period cash flow 4.17M 9.72M 5.92M 4.20M 8.64M
End period cash flow 2.40M 4.17M 9.72M 5.92M 4.20M
Total cash from operating activities -3.84100M -5.36100M -5.47400M -0.48053M -5.25175M
Issuance of capital stock 2.14M 0.00000M 10.01M 2.40M 1.01M
Depreciation 0.40M 0.37M 0.35M 0.59M 0.38M
Other cashflows from investing activities - -0.06400M - - -0.15973M
Dividends paid - - - - -
Change to inventory 0.88M -0.11500M 0.53M 1.56M -1.90601M
Change to account receivables 0.21M -0.21500M -0.29100M 1.37M -0.45561M
Sale purchase of stock - 0.00000M -0.70500M -0.08457M -0.16592M
Other cashflows from financing activities -0.03200M -0.08100M 0.08M 0.08M 0.27M
Change to netincome - - 1.35M -0.14314M 2.69M
Capital expenditures 0.04M 0.12M 0.08M 0.17M 0.30M
Change receivables - - - - -0.45561M
Cash flows other operating - - - - 1.28M
Exchange rate changes - - - - -0.00812M
Cash and cash equivalents changes - - - - -4.44172M
Change in working capital 0.27M -0.62500M -0.03800M 2.91M -1.85299M
Stock based compensation 0.46M 0.84M 1.19M 1.26M 1.35M
Other non cash items 0.00400M 0.03M 0.17M -0.71915M 2.32M
Free cash flow -3.87800M -5.47600M -5.55200M -0.65087M -5.54733M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BMRA
Biomerica Inc		 0.06 3.24% 1.91 - - 1.54 2.01 1.28 -5.4197
ABT
Abbott Laboratories		 2.41 2.74% 90.24 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 5.38 1.77% 310.07 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 1.33 1.68% 80.60 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 0.77 1.74% 45.10 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria. The company has strategic partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs for launching the inFoods platform in Canada. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Biomerica Inc

17571 Von Karman Avenue, Irvine, CA, United States, 92614

Key Executives

Name Title Year Born
Mr. Zackary S. Irani Chairman & CEO 1966
Mr. Allen C. Barbieri Exec. Vice-Chairman & Corp. Sec. 1958
Mr. Steven Sloan CFO & Treasurer 1970
Ms. Lucy Liu Ph.D. Director of Manufacturing & Technical Operations NA
Hans Boehringer Sr. VP of POC R&D NA
Mr. Robert W. Carlson Chief Commercial Officer NA
Mr. Zackary S. Irani Chief Executive Officer 1966
Mr. Allen C. Barbieri Executive Vice-Chairman of the Board & Corporate Secretary 1958
Mr. Gary Lu CPA Principal Accounting Officer & CFO 1981
Mr. Zackary S. Irani CEO & Director 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions